A 4-week Multi-center, Single-masked, Randomized, Latanoprost-controlled, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of RKI983 (0.05% and 0.10%) Ophthalmic Solution Given Twice a Day Versus Once Daily Latanoprost 0.005%, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Novartis Pharmaceuticals1 site in 1 country276 target enrollmentJanuary 2009

ConditionsGlaucoma Ocular Hypertension

InterventionsRKI983A Latanoprost

DrugsRKI983A Latanoprost

Overview

Phase: Phase 1
Intervention: RKI983A
Conditions: Glaucoma
Sponsor: Novartis Pharmaceuticals
Enrollment: 276
Locations: 1
Primary Endpoint: Mean reduction of the daily average intraocular pressure (IOP) .
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.

Registry

clinicaltrials.gov

Start Date

January 2009

End Date

April 2009

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Male

Investigators

Sponsor

Novartis Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Females must be post-menopausal or surgically sterile, or must use concomitantly two acceptable forms of effective contraception
•Clinical diagnosis of POAG or OH
•For study eyes not previously treated with anti-glaucoma medications
•IOP must be ≥ 22 mm Hg at least at two assessment time-points at Screening, and
•IOP must be ≥ 22 mm Hg at least at two assessment time-points at Baseline, and
•IOP must be ≥ 20 mm Hg and ≤ 36 mm Hg at all Screening and Baseline assessment time-points.
•Or for study eyes previously treated with anti-glaucoma medications
•IOP must be ≥ 14 mm Hg and ≤ 24 mm Hg at least at two assessment time-points at Screening.
•IOP must be ≥ 22 mm Hg at least at two assessment time-points at Baseline (after wash-out)
•IOP must be ≥ 20 mm Hg and ≤ 36 mm Hg at all Baseline assessment time-points

Exclusion Criteria

•History of or current clinically significant ocular conditions in either eye that would contraindicate the use of an investigational drug or latanoprost (e.g. active intraocular inflammation), or that might affect interpretation of the results of the study.
•History or presence of clinically significant medical problems that contraindicate the use of an investigational drug or latanoprost, including but not limited to:
•Uncontrolled hypertension with systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg measured at more than one blood pressure reading at Screening or Baseline;
•myocardial infarction within the 3 months period prior to randomization;
•active severe viral infections such as active encephalitis, meningitis, hepatitis, herpes simplex, or herpes zoster (minor viral upper respiratory infections such as colds do not require exclusion.)
•Presence of moderate or severe (grade 2 or 3) conjunctival hyperemia in the study eye at Baseline Visit.
•Argon laser trabeculoplasty or any prior IOP lowering surgery in the study eye.
•Ocular surgery in the study eye within 3 months prior to the Screening Visit.
•Other protocol-defined inclusion/exclusion criteria may apply

Arms & Interventions

1

Intervention: RKI983A

2

Intervention: RKI983A

3

Intervention: Latanoprost

Outcomes

Primary Outcomes

Mean reduction of the daily average intraocular pressure (IOP) .

Time Frame: from Baseline to Day 29

Secondary Outcomes

Mean IOP reduction at each assessment time-point(from Baseline to Day 8, 15, 22 and 29)
Mean reduction of the daily average IOP(from Baseline to Days 8, 15 and 22)
Frequency of adverse events(4 weeks)